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Abstract
Background: mTOR signaling pathway and its downstream serine/threonine kinase p70S6k were
frequently activated in human cancers. The dysregulation of the mTOR pathway has been found to
be a contributing factor of a variety of different cancer. To investigate the role of mTOR signal
pathway in the stepwise development of gastric carcinomas, we analyzed the correlations between
the mTOR and P70S6K expression and clinic pathological factors and studied its prognostic role in
gastric carcinomas.
Methods: mTOR and phospho-p70S6K proteins were examined by immunohistochemistry on
tissue microarray containing gastric carcinomas (n = 412), adenomas (n = 47) and non-neoplastic
mucosa (NNM, n = 197) with a comparison of their expression with clinicopathological parameters
of carcinomas.
Results: There was no difference of mTOR expression between these three tissues (p > 0.05).
Cytoplasmic phospho(p)-P706SK was highly expressed in adenoma, compared with ANNMs (p <
0.05), whereas its nuclear expression was lower in gastric carcinomas than gastric adenoma and
ANNMs (p < 0.05). These three markers were preferably expressed in the older patients with
gastric cancer and intestinal-type carcinoma (p < 0.05). mTOR expression was positively correlated
with the cytoplasmic and nuclear expression of p-P70S6K(p < 0.05). Nuclear P70S6K was inversely
linked to tumor size, depth of invasion, lymph node metastasis and UICC staging (p < 0.05).
Univariate analysis indicated that expression of mTOR and nuclear p-P70S6K was closely linked to
favorable prognosis of the carcinoma patients (p < 0.05). Multivariate analysis showed that age,
depth of invasion, lymphatic invasion, lymph node metastasis, Lauren's classification and mTOR
expression were independent prognostic factors for overall gastric carcinomas (p < 0.05).
Conclusion: Aberrant expression of p-P70S6K possibly contributes to pathogenesis, growth,
invasion and metastasis of gastric carcinomas. It was considered as a promising marker to indicate
the aggressive behaviors and prognosis of gastric carcinomas.
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Introduction
Gastric carcinoma ranks as the world's second leading
cause of cancer mortality behind lung cancer despite a
sharp worldwide decline in both its incidence and mortal-
ity since the second half of the 20th century. It continues
to be a major health problem because of the slow decrease
in incidence in Asia and high mortality of diagnosed gas-
tric carcinoma in West [1]. Therefore, it is of much signif-
icance for the prevention, treatment and prognosis
evaluation of gastric cancer to clarify its molecular mech-
anisms and find out a good biomarker to indicate its car-
cinogenesis and subsequent progression.
The mammalian target of rapamycin (mTOR) also known
as FK506 binding protein 12-rapamycin associated pro-
tein 1 is a serine/threonine protein kinase that supports
cell growth, cellular metabolism, cell proliferation, cell
motility, cell survival, protein synthesis, and transcription
such as angiogenesis and autophagy. mTOR that is an evo-
lutionarily conserved serine-threonine kinase of a 289-
kDa in length belongs to the phosphoinositide 3-kinase
(PI3K)-related kinase family. mTOR is composed of an N-
term; 20 tandem repeats-HEAT which are implicated in
protein-protein interactions; and a C-term which includes
a FAT domain, a FBR domain, a kinase domain, a NDR
domain and a FATC domain. The FATC domain is essen-
tial to mTOR activity and the deletion of a single amino
acid from this domain abrogates the activity. mTOR can
be autophosphorylated via its intrinsic serine/threonine
kinase activity. mTOR exerts its multiple functions in the
context of two different multiprotein complexes: mTOR
complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
mTORC1 is composed of mTOR, Raptor, mLST8, and
PRAS40, and importantly activates p70 ribosomal protein
S6 kinase and inactivates eIF4E binding protein 1, which
promotes protein translation and cell growth. Conversely,
mTORC2 is composed of mTOR, Rictor, Sin1, and mLST8,
phosphorylates and activates another member of the AGC
kinase family, Akt. Current research indicates that mTOR
integrates the input from multiple upstream pathways,
including insulin, growth factors (such as IGF-1 and IGF-
2), and mitogens. mTOR also functions as a sensor of cel-
lular nutrient and energy levels and redox status [2-5].
P70 S6 kinase (p70S6K) is activated in a signaling path-
way that includes mTOR. P70S6K is a mitogen-activated
Ser/Thr protein kinase that is required for cell growth and
G1 cell cycle progression. This kinase is controlled by mul-
tiple phosphorylation events located within the catalytic,
linker and pseudosubstrate domains and subsequently
phosphorylates specifically ribosomal protein S6. Activa-
tion occurs via phosphorylation at ser411, Thr421 and
Ser424 within the pseudosubstrate region. Phosphoryla-
tion of Thr229 in the catalytic domain and Thr389 in the
linker domain are most critical for kinase function. Stim-
ulation of mammalian cells by a variety of mitogenic
stimuli results in a rapid, biphasic activation of p70S6K.
Inhibition of p70 activity inhibits the entry into S phase of
the cell cycle and exhibits cell cycle arrest at G0/G1 phase,
suggesting that the activation of p70S6k plays an obliga-
tory role in mediating mitogenic signals during cell activa-
tion [6-8].
mTOR signaling pathway and its downstream serine/thre-
onine kinase p70S6k were frequently activated in human
cancers and the dysregulation of the mTOR pathway is
implicated as a contributing factor to various human dis-
ease processes, especially various types of cancer[5,6,8-
11]. However, the mTOR/p70S6K signaling pathway in
gastric carcinomas has not been investigated so far, which
impel the authors to investigate the role of mTOR/p70S6K
signaling pathway for finding a novel target for the anti-
cancer drugs in gastric carcinoma. In the present study, we
observed that mTOR and P70S6K expression were exam-
ined in gastric carcinoma, adjacent non-tumorous
mucosaand adenoma, and compared with the clinico-
pathological parameters of tumors to explore the clinico-
pathological significance and molecular role of the mTOR
signal pathway in the stepwise development of gastric car-
cinomas.
Materials and methods
Subjects
Gastric carcinomas (n = 421) were collected from the sur-
gical resection, adenoma (n = 45) from endoscopic biopsy
or polypectomy, and gastritis (n = 49) from the endo-
scopic biopsy in Shengjing Hospital of China Medical
University and the First Affiliated Hospital of China Med-
ical University between 1993 and 2006. All carcinomas
were adenocarcinomas and the adenoma group was free
from non-neoplastic polyp types, leiomyomas and benign
GIST's. The patients with gastric carcinoma were 293 men
and 126 women (29~91 years, mean = 65.4 years).
Among them, 156 cases have carcinomas accompanied
with lymph node metastasis. None of the patients under-
went chemotherapy or radiotherapy before surgery. They
all provided consent for use of tumour tissue for clinical
research and our University Ethical Committee approved
the research protocol. We followed up all patients by con-
sulting their case documents or through telephone.
Pathology
All tissues were fixed in 4% neutralised formaldehyde,
embedded in paraffin and incised into 4 mm sections.
These sections were stained by haematoxylin-and-eosin
(HE) to confirm their histological diagnosis and other
microscopic characteristics. The staging for each gastric
carcinoma was evaluated according to the Union Interna-
tionale Contre le Cancer (UICC) system for the extent of
tumour spread [12]. Histological architecture of gastricJournal of Experimental & Clinical Cancer Research 2009, 28:152 http://www.jeccr.com/content/28/1/152
Page 3 of 9
(page number not for citation purposes)
carcinoma was expressed in terms of Lauren's classifica-
tion [13,14]. Furthermore, tumour size, depth of inva-
sion, lymphatic and venous invasion were determined.
Tissue microarray (TMA)
Prior to TMA construction, all tissue slides were his-
topathologically re-evaluated by one pathologist and.
Two 2.0-mm tissue cores were taken from representative
areas of gastric samples using a manual arraying device
(MTA-1; Beecher Inc., Sun Prairie, WI, USA) and mounted
in a new recipient block. Four-μm-thick sections were
consecutively incised from the recipient block and trans-
ferred to poly-lysine-coated glass slides. HE staining was
performed on TMA for confirmation of tumor tissue.
Immunohistochemistry
For the immunohistochemical procedure, 4-μm-thick sec-
tions were deparaffinized with xylene and rehydrated
through an alcohol gradient. The sections were quenched
with 3% hydrogen peroxide in absolute methanol for 20
min to block endogenous peroxidase activity, and heated
in a microwave for 15 min in citrate buffer (0.01 mol/L,
pH 6.0) to retrieve the antigen. The sections were incu-
bated with rabbit anti-mTOR antibody (Clone ID: Y392,
1612-1, Epitomics, USA; 1:250) and anti-phospho-p70 s6
kinase (pT389. Clone ID: E175, 1175-1, Epitomics, USA;
1:50) for 60 min, followed by exposure to the anti-rabbit
Envison-PO (DAKO, USA) antibody for 60 min. Binding
sites were visualized with 3, 3'-diaminobenzidine (DAB)
with the 5-min reaction. After each treatment, the slides
were washed with TBST (10 mM Tris-HCl, 150 mM NaCl,
0.1% Tween 20) three times for 1 min. After counter-
stained with Mayer's haematoxylin, the sections were
dehydrated, cleared and mounted. Omission of the pri-
mary antibody was used as a negative control.
As indicated in Figure 1, mTOR was positively localized in
the cytoplasm, whereas P70S6K in the cytoplasm and
nucleus. One hundred cells were randomly selected and
counted from 5 representative fields of each section
blindly by three independent observers. The positive per-
centage of counted cells was graded semi-quantitatively
according to a four-tier scoring system: negative (-),
0~5%; weakly positive (+), 6~25%; moderately positive
(++), 26~50%; and strongly positive (+++), 51~100%.
Statistical Analysis
Statistical evaluation was performed using Spearman cor-
relation test to analyze the rank data. Kaplan-Meier sur-
vival plots were generated and comparisons between
survival curves were made with the log-rank statistic. The
Cox's proportional hazards model was employed for mul-
Immunohistochemical staining in gastritis, gastric adenoma and carcinoma Figure 1
Immunohistochemical staining in gastritis, gastric adenoma and carcinoma. Note mTOR positivity was strongly 
observed in the cytoplasm, while P70S6K in the cytoplasm and nucleus. mTOR expression was observed in non-cancerous 
mucosa (a, +++), adenoma (b, +++) and carcinoma(c, +++). P70S6K protein was immunoreactive in non-neoplastic mucosa (d, 
+++), adenoma (e, +++) and carcinoma (f, +++).Journal of Experimental & Clinical Cancer Research 2009, 28:152 http://www.jeccr.com/content/28/1/152
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tivariate analysis. p < 0.05 was considered as statistically
significant. SPSS 10.0 software was employed to analyze
all data.
Results
mTOR and p70 S6 kinase expression in gastric carcinomas
As showed in Figure 1, mTOR was positively immunos-
tained in the cytoplasm of gastric epithelial cells, adeno-
mas and carcinomas. Overall, mTOR expression was
detected respectively in 66.3% of NNM (n = 197). 47 out
of 67 adenoma patients (70.1%), and 255 out of total 412
gastric carcinoma patients (61.2%). Statistically, there was
no significance between these three groups (p > 0.05,
Table 1). As summarized in Table 2, cytoplasmic P706SK
was highly expressed in adenoma (53.7%, 37/67), com-
pared with NNM (34.5%, 68/197, p < 0.05). However,
nuclear p70S6K expression was positive in 216 cases of
404 gastric carcinomas (59.5%), lower than gastric ade-
noma (83.6%, 56/67) and ANTMs (78.2%, 154/197, p <
0.05, Table 3)
These three markers were preferably expressed in the older
patients with gastric cancer and intestinal-type carcinoma
(p < 0.05, Table 4, Table 5 and Table 6). mTOR expression
was positively correlated with the cytoplasmic and nuclear
expression of P70S6K (p < 0.05, Table 4). mTOR expres-
sion was inversely correlated with tumour size, depth of
invasion, lymphatic invasion, lymph node metastasis and
UICC staging (p < 0.05), but not with sex or venous inva-
sion (p > 0.05, Table 4). Nuclear P70S6K expression was
inversely linked to tumor size, depth of invasion, lymph
node metastasis and UICC staging (p < 0.05, Table 6).
Univariate and multivariate survival analysis
Follow-up information was available on 412 gastric carci-
noma patients for periods ranging from 0.2 months to
12.2 years (median = 67.3 months). The 122 patients died
from carcinoma and several cases dying from other dis-
ease has been excluded. Figure 2 showed survival curves
stratified according to mTOR, cytoplasmic or nuclear
P70S6K expression for gastric carcinomas. Univariate
analysis using the Kaplan-Meier method indicated cumu-
lative survival rate of patients with weak, moderate or
strong mTOR and nuclear p70S6K expression to be obvi-
ously higher than without its expression (p < 0.05). Mul-
tivariate analysis using Cox' s proportional hazard model
indicated that age, depth of invasion, lymphatic invasion,
lymph node metastasis, Lauren's classification and mTOR
expression (p < 0.05), but not sex, tumor size, UICC stag-
ing, cytoplasmic or nuclear P70S6K expression were inde-
pendent prognostic factors for overall gastric carcinomas
(p > 0.05, Table 7).
Discussion
Mammalian target of rapamycin (mTOR) is also known as
FKBP-rapamycin-associated protein or rapamycin and
FKBP target and functions as a serine/threonine protein
kinase to sense adenosine triphosphate and amino acids
to balance nutrient availability and cell growth. When suf-
ficient nutrients are available, mTOR is phosphorylated
via the phosphoinositide 3-kinase (PI3K)/AKT signaling
pathway, transmits a positive signal to p70 S6 kinase
(p70S6K), and participates in the inactivation of the
eukaryotic translation initiation factor 4E inhibitor,
4EBP1. Therefore, mTOR plays a key role in cellular
growth and homeostasis, and its regulation is frequently
altered in tumors [8,15].
Although mTOR protein can shuttle between the nucleus
and cytoplasm [16,17], we only observed its cytoplasmic
distribution in line with the figure of its antibody data
sheet. The phenomenon might be due to cell specificity
and different antibody. In the present study, the antibody
was produced with a synthetic peptide corresponding to
residues near the C-term of PI3K/PI4K domain of human
mTOR/FRAP as an immunogen. In addition, we found no
Table 1: mTOR expression in gastric carcinogenesis.
Groups N mTOR expression
- + ++ +++ PR(%)
Non-neoplastic mucosa 197 65 89 30 13 66.3
Adenoma 67 20 29 16 2 70.1
Carcinomas 412 157 154 78 23 61.2
PR, positive rate; p > 0.05
Table 2: CytoplasmicP70S6K expression in gastric 
carcinogenesis
Groups N Cytoplasmic P70S6K expression
- + ++ +++ PR(%)
Non-neoplastic mucosa 197 129 43 24 1 34.5
Adenoma 67 30 31 5 0 53.7*
Carcinomas 394 237 115 39 3 39.8
PR, positive rate
*compared with non-neoplastic mucosa, p < 0.05
Table 3: Nuclear P70S6K expression in gastric carcinogenesis
Groups N Nuclear P70S6K expression
- + ++ +++ PR(%)
Non-neoplastic mucosa 197 43 67 62 25 78.2
Adenoma 67 11 20 28 8 83.6
Carcinomas 404 188 123 73 20 59.5*
*compared with non-neoplastic mucosa or adenoma, p < 0.001Journal of Experimental & Clinical Cancer Research 2009, 28:152 http://www.jeccr.com/content/28/1/152
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difference in mTOR expression between gastric ANTC,
adenoma and carcinoma, which suggested its role of
growth-regulating in all gastric epithelial and lesion cells.
However, its active form, phosphorylated mTOR might
contribute to the carcinogenesis according to the literature
[18-23]. In contrast, its down-stream target, the aberrant
expression of cytoplasmic and nuclear phoshorylated
p70S6K occurred in gastric adenoma-adenocarcinoma
sequence. For instance, adenoma displayed higher cyto-
plasmic expression of active p70S6K than NNM group,
whereas nuclear counterpart was less expressed in carci-
noma than NNM and adenoma. It was speculated that dif-
ferent subcelluar distribution of phospho-p70S6K might
have distinct biological function in the malignant trans-
formation of gastric epithelial cells.
The 70-kDa S6 kinase (p70S6K) is a cytoplasmic Ser/Thr
kinase that is mainly known to regulate protein transla-
tion through phosphorylation of the 40S ribosomal pro-
tein S6. Activation of p70S6K is achieved through
phosphorylation on multiple Ser/Thr residues by stimula-
tion with growth factors such as epidermal growth factor
(EGF), thrombin, and lysophosphatidic acid
(LPA)[23,24]. To the role of phopsho-p0S6K protein in
the progression of gastric carcinoma, its expression was
compared with the aggressive behaviors of carcinoma and
for the first time found that nuclear phosphor-P70S6K
expression was inversely linked to tumor size, depth of
invasion, lymph node metastasis and UICC staging. It was
suggested that down-regulated expression of nuclear
phospho-P70S6K was involved in the growth, invasion
and metastasis of gastric carcinoma and might be
employed to indicate the biological behaviors of gastric
carcinoma in clinicopathological practice.
Although gastric cancer is malignant tumor originating
from the same gastric epithelium, its morphological fea-
tures vary substantially with the individual patients [13].
Table 4: Relationship between mTOR expression and clinicopathological features of gastric carcinomas
Clinicopathological features n mTOR expression
-+ + + + + + P R ( % )P value
Age(years) 0.042
<65 163 64 66 30 3 60.7
≥65 249 93 88 48 20 62.7
Sex 0.089
male 288 109 101 56 22 62.2
Female 124 48 53 22 1 61.3
Tumor size(cm) 0.457
<4 221 81 83 44 13 63.3
≥4 191 76 71 34 10 60.2
Depth of invasion 0.361
Tis-1 222 79 86 45 12 64.4
T2-4 190 78 68 33 11 58.9
Lymphatic invasion 0.845
-2 6 7 9 9 1 0 3 5 1 1 4 6 2 . 9
+ 145 58 51 27 9 60.0
Venous invasion 0.063
- 358 140 135 66 17 60.9
+ 5 41 71 91 2 6 6 8 . 5
Lymph node metastasis 0.168
-2 6 3 9 0 1 0 5 5 5 1 3 6 5 . 8
+ 149 67 49 23 10 55.0
UICC staging 0.898
0-I 234 87 90 45 12 62.8
II-IV 178 70 64 33 11 60.7
Lauren classification 0.000
Intestinal type 230 71 84 56 19 69.1
Diffuse type 173 81 67 21 4 53.2
Cytoplasmic P70S6K expression 0.000
- 207 109 72 22 4 47.3
+~+++ 151 27 57 48 19 82.1
Nuclear P70S6K expression 0.000
- 162 95 48 15 4 41.4
+~+++ 206 39 90 58 19 81.1
PR = positive rate; Tis = carcinoma in situ; T1 = lamina propria and submucosa; T2 = muscularis propria and subserosa; T3 = exposure to serosa; T4 
= invasion into serosa; UICC = Union Internationale Contre le CancerJournal of Experimental & Clinical Cancer Research 2009, 28:152 http://www.jeccr.com/content/28/1/152
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According to Lauren's classification, intestinal-type carci-
nomas are characterized by cohesive carcinoma cells
forming gland-like tubular structures with expanding or
infiltrative growth pattern. The cell cohesion is less appar-
ent or absent in diffuse-type carcinoma and cancer cells
diffusely spread in the gastric wall lesions. Tumors that
contain approximately equal quantities of intestinal and
diffuse components are called mixed carcinoma [13,14].
These three markers were preferably expressed in the older
patients with gastric cancer and intestinal-type carcinoma.
Here, it was noted that mTOR, cytoplasmic and nuclear
P70SK6 expression was higher in intestinal-than diffuse-
type carcinomas, indicating that these three markers
might play an important role in intestinal-type carcino-
genesis, but less in de novo carcinogenic pathway and
underlie the molecular basis for differentiation of both
carcinomas.
To clarify the prognostic significance of mTOR, cytoplas-
mic or nuclear P70S6K expression, we here analyzed their
relation with the survival of 412 patients with gastric car-
cinoma and found a close relationship link between the
positivity of mTOR and nuclear phospho-P70S6K expres-
sion and favorable survival. Multivariate analysis demon-
strated six independent prognostic factors such as age,
depth of invasion, lymphatic invasion, lymph node
metastasis, Lauren's classification and mTOR expression
were independent prognostic factors for overall gastric
carcinomas. However, several evidences indicated that
phosphor-mTOR expression was closely linked to the
poor prognosis of the patients with cervical adenocarci-
oma or hepatocellular carcinoma [18,25]. PS6K overex-
pression was reported to correlate with worse distant
disease-free survival of early-stage breast cancer patients.
The paradoxical phenomenon might be attributed to the
different mTOR types or different subcellular distribution
of p70S6K protein. Here, nuclear p70S6K was inversely
related to the tumor size, depth of invasion, lymph node
metastasis and UICC staging, which are aggressive appear-
ances of gastric cancer. The finding indicated p70 S6 phos-
Table 5: Relationship between cytoplasmic P70S6K expression and clinicopathological features of gastric carcinomas
Clinicopathological features N Cytoplasmic P70S6K expression
- + ++ +++ PR(%) P value
Age(years) 0.001
<65 158 108 37 13 0 31.6
≥65 236 129 78 26 3 45.3
Sex 0.161
male 273 162 76 32 3 40.7
F e m a l e 1 2 1 7 53 970 3 8 . 0
Tumor size(cm) 0.393
<4 199 117 58 22 2 41.2
≥4 195 120 57 17 1 38.5
Depth of invasion 0.747
Tis-1 197 117 59 19 2 40.6
T2-4 197 120 56 20 1 39.5
Lymphatic invasion 0.739
- 247 150 73 21 3 39.3
+ 147 87 42 18 0 40.8
Venous invasion 0.452
- 235 202 101 29 3 56.6
+ 5 53 51 01 0 0 3 6 . 4
Lymph node metastasis 0.550
- 239 140 74 23 2 41.4
+ 155 97 41 16 1 37.4
UICC staging 0.996
0-I 213 128 63 20 2 39.9
II-IV 181 109 52 19 1 39.8
Lauren classification 0.000
Intestinal type 209 96 81 30 2 54.1
Diffuse type 174 134 30 9 1 23.0
Nuclear P70S6K expression 0.000
- 188 153 28 7 0 18.6
+~+++ 202 83 84 32 3 58.9
PR = positive rate; Tis = carcinoma in situ; T1 = lamina propria and submucosa; T2 = muscularis propria and subserosa; T3 = exposure to serosa; T4 
= invasion into serosa; UICC = Union Internationale Contre le CancerJournal of Experimental & Clinical Cancer Research 2009, 28:152 http://www.jeccr.com/content/28/1/152
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phorylation in the nucleus might play some inhibitory
role in gastric cancer and subsequent progression distinct
from that in the cytoplasm.
Conclusion
Aberrant expression of p-P70S6K might play an important
role of malignant transformation of gastric epithelial cells
and was closely related to growth, invasion, metastasis
and prognosis of gastric carcinomas and was considered
as a promising marker to indicate the pathobiological
behaviors. The distinct expression of mTOR and p-
P70S6K could be employed to differentiate the intestinal-
and diffuse-type carcinomas and underlay the molecular
mechanism about the differentiation of both carcinomas.
Table 6: Relationship between nuclear P70S6K expression and clinicopathological features of gastric carcinomas
Clinicopathological features N Nuclear P70S6K expression
-+ + + + + + P R ( % )P value
Age(years) 0.042
<65 165 86 49 20 10 47.9
≥65 39 102 74 53 10 57.3
Sex 0.172
male 282 127 85 54 16 55.0
Female 122 61 38 19 4 50
Tumor size(cm) 0.001
<4 210 86 59 52 13 59.0
≥4 194 102 64 21 7 47.4
Depth of invasion 0.000
Tis-1 208 81 61 53 13 61.1
T2-4 196 107 62 20 7 45.4
Lymphatic invasion 0.171
- 257 114 77 54 12 55.6
+ 147 74 46 19 8 49.7
Venous invasion 0.611
- 340 164 98 65 13 51.8
+ 6 42 42 5 87 6 2 . 5
Lymph node metastasis 0.000
- 248 102 72 59 15 58.9
+ 156 86 51 14 5 44.9
UICC staging 0.002
0-I 213 93 64 53 13 61.0
II-IV 181 95 59 20 7 47.5
Lauren classification 0.000
Intestinal type 221 76 70 58 17 65.6
Diffuse type 172 105 52 12 3 40.0
PR = positive rate; Tis = carcinoma in situ; T1 = lamina propria and submucosa; T2 = muscularis propria and subserosa; T3 = exposure to serosa; T4 
= invasion into serosa; UICC = Union Internationale Contre le Cancer
Table 7: Multivariate analysis of clinicopathological variables for survival with gastric carcinomas
Clinicopathological parameters Relative risk (95%CI) p value
Age(≥ 65 years) 1.857(1.206-2.859) 0.005
Sex(male) 1.587(0.977-2.577) 0.062
Tumor size(≥ 4) 1.372(0.776-2.426) 0.277
Depth of invasion (T2-4) 2.793(1.323-5.898) 0.007
Lymphatic invasion(+) 2.086(1.230-3.538) 0.006
Venous invasion(+) 1.080(0.663-1.758) 0.758
Lymph node metastasis(+) 2.842(1.463-5.523) 0.002
Lauren's classification (diffuse-tape) 1.914(1.178-3.110) 0.009
mTOR (+-+++) 0.737(0.547-0.992) 0.044
Cytoplasmic P70S6K expression (+-+++) 1.061(0.765-1.472) 0.724
Nuclear P70S6K expression (+-+++) 0.854(0.625-1.166) 0.320
CI = confidence interval.Journal of Experimental & Clinical Cancer Research 2009, 28:152 http://www.jeccr.com/content/28/1/152
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Nuclear p-p70S6K was a good marker to indicate the favo-
rable prognosis of gastric carcinoma patients, albeit
dependent on other parameters, but mTOR expression
was an independent factor for the prognosis.
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Correlation between mTOR or p70S6K status and prognosis of the gastric carcinoma patients Figure 2
Correlation between mTOR or p70S6K status and prognosis of the gastric carcinoma patients. Kaplan-Meier 
curves for cumulative survival rate of patients with gastric carcinomas according to the mTOR(A) and cytoplasmic(B) or 
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